Literature DB >> 21983363

Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice.

Joshua Tobias1, Ann-Mari Svennerholm, Nils I A Carlin, Michael Lebens, Jan Holmgren.   

Abstract

Coli surface antigen 6 (CS6) is one of the most prevalent non-fimbrial colonization factors (CFs) of enterotoxigenic Escherichia coli (ETEC) bacteria, which are the most common cause of diarrhea among infants and children in developing countries. Since immune protection against ETEC is mainly mediated by locally produced IgA antibodies in the gut, much effort is focused on the development of an oral CF-based vaccine. Previous work has described the preparation of candidate E. coli vaccine strains expressing immunogenic amounts of fimbrial CF antigens such as CFA/I and CS2, which are retained after formalin treatment. However, attempts to generate E. coli expressing immunogenic amounts of CS6 and to preserve the immunological activity of the CS6 protein in a killed whole-cell vaccine have failed until now. Here we describe the construction of a recombinant non-toxigenic E. coli strain, with thyA as a non-antibiotic-based selection, which expresses large amounts of CS6 antigen on the bacterial surface, and show that phenol inactivation of the bacteria does not destroy the CS6 antigen properties. Oral immunization of mice with such phenol-killed CS6 over-expressing E. coli bacteria induced strong fecal and intestinal IgA and serum IgG+IgM antibody responses to CS6 that exceeded the responses induced by an ETEC reference strain naturally expressing CS6 and previously used as a vaccine strain. Our data indicate that the described phenol-inactivated non-toxigenic and CS6 over-expressing E. coli strain may be a useful component in an oral ETEC vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983363     DOI: 10.1016/j.vaccine.2011.09.096

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

2.  Antibacterial activity of silver and zinc nanoparticles against Vibrio cholerae and enterotoxic Escherichia coli.

Authors:  Wesam Salem; Deborah R Leitner; Franz G Zingl; Gebhart Schratter; Ruth Prassl; Walter Goessler; Joachim Reidl; Stefan Schild
Journal:  Int J Med Microbiol       Date:  2014-11-11       Impact factor: 3.473

3.  Stability of the Encoding Plasmids and Surface Expression of CS6 Differs in Enterotoxigenic Escherichia coli (ETEC) Encoding Different Heat-Stable (ST) Enterotoxins (STh and STp).

Authors:  Joshua Tobias; Astrid Von Mentzer; Patricia Loayza Frykberg; Martin Aslett; Andrew J Page; Åsa Sjöling; Ann-Mari Svennerholm
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

4.  An LTB-entrapped protein in PLGA nanoparticles preserves against enterotoxin of enterotoxigenic Escherichia coli.

Authors:  Emad Kordbacheh; Shahram Nazarian; Davoud Sadeghi; Abbas Hajizadeh
Journal:  Iran J Basic Med Sci       Date:  2018-05       Impact factor: 2.699

5.  Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic Escherichia coli as a prophylactic against diarrhea.

Authors:  K R Talaat; C K Porter; A L Bourgeois; T K Lee; C A Duplessis; M Maciel; R L Gutierrez; B DeNearing; B Adjoodani; R Adkinson; K J Testa; B Feijoo; A N Alcala; J Brubaker; A Beselman; S Chakraborty; D Sack; J Halpern; S Trop; H Wu; J Jiao; E Sullivan; M S Riddle; S S Joseph; S T Poole; M G Prouty
Journal:  Gut Microbes       Date:  2020-03-13

6.  A combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles.

Authors:  Deborah R Leitner; Sabine Lichtenegger; Philipp Temel; Franz G Zingl; Desiree Ratzberger; Sandro Roier; Kristina Schild-Prüfert; Sandra Feichter; Joachim Reidl; Stefan Schild
Journal:  Front Microbiol       Date:  2015-08-11       Impact factor: 5.640

Review 7.  Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.

Authors:  Maricarmen Rojas-Lopez; Ricardo Monterio; Mariagrazia Pizza; Mickaël Desvaux; Roberto Rosini
Journal:  Front Microbiol       Date:  2018-03-20       Impact factor: 5.640

8.  Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.

Authors:  Firdausi Qadri; Marjahan Akhtar; Taufiqur R Bhuiyan; Mohiul I Chowdhury; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Anna Lundgren; Gudrun Wiklund; Joanna Kaim; Madeleine Löfstrand; Nils Carlin; A Louis Bourgeois; Nicole Maier; Alan Fix; Thomas Wierzba; Richard I Walker; Ann-Mari Svennerholm
Journal:  Lancet Infect Dis       Date:  2019-11-19       Impact factor: 25.071

9.  A CssA, CssB and LTB chimeric protein induces protection against Enterotoxigenic Escherichia coli.

Authors:  Samane Bagheri; Seyed Latif Mousavi Gargari; Iraj Rasooli; Shahram Nazarian; Masoome Alerasol
Journal:  Braz J Infect Dis       Date:  2014-01-03       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.